Augurex Life Sciences
Augurex Life Sciences is a Vancouver-based diagnostics company that develops and commercializes proprietary 14-3-3eta biomarker blood tests — JOINTstat for rheumatoid arthritis and SPINEstat for axial spondyloarthritis — distributed through major clinical laboratory networks in North America and the UK.
- Company typePrivate
- Founded2011
- HeadquartersVancouver, Canada
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Augurex Life Sciences does
Augurex Life Sciences Corp. is a Vancouver, British Columbia-based commercial-stage diagnostics company that develops and commercializes biomarker-driven blood tests for autoimmune conditions, with primary focus on rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA). The company's core technology is the proprietary 14-3-3eta biomarker platform — a joint-derived intracellular protein that is externalized during joint inflammation and acts as a proinflammatory ligand, driving joint erosion and damage through the FOXO3-Snail axis and downstream production of TNF-α, IL-6, RANKL, and MMP-9. Augurex's product portfolio includes JOINTstat (an ELISA-based blood test measuring 14-3-3eta protein levels for RA diagnosis and monitoring) and SPINEstat (a first-in-class multiplex immunoassay detecting autoantibodies to 14-3-3eta epitopes for axSpA diagnosis), as well as analyte-specific reagents (ASRs) sold to US clinical laboratories for development of their own laboratory-developed tests.
The company operates a B2B diagnostics model, monetizing primarily through licensing/royalty arrangements with major clinical laboratory networks and through ASR reagent sales. In the US, tests are distributed via Quest Diagnostics (under an exclusive license covering 14-3-3eta), Labcorp, ARUP Laboratories, and Sonic Healthcare USA. In Canada, distribution is through Dynacare and MitogenDx. End-user demand is driven by rheumatologist adoption, supported by active participation in major rheumatology conferences (ACR, EULAR, SPARTAN), patient advocacy partnerships, and over 10 years of peer-reviewed clinical evidence spanning 2,000+ evaluated patients. Regulatory clearances include Health Canada approvals for both products, UKCA marking in Great Britain, FDA Breakthrough Device Designation for SPINEstat, ISO 13485:2016 certification, and MDSAP certification.
Augurex is a privately held company with 1-10 employees, founded circa 2011 by Dr. Norma Biln and Dr. Anthony Marotta. In August 2024, veteran life sciences executive Neil Klompas (former President and COO of Zymeworks) was appointed President and CEO, with co-founder Dr. Biln transitioning to Chair of the Board. The company received a $5M CAD grant from PacifiCan (Canadian government) in 2024, and is recognized as Life Sciences BC's 2024 Emerging Company of the Year and a finalist for the ADLM 2026 Disruptive Technology Award.
Augurex Life Sciences firmographics
Firmographics- Name
- Augurex Life Sciences
- Legal name
- Augurex Life Sciences Corp.
- Website
- https://augurex.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Augurex Life Sciences is a Vancouver-based diagnostics company that develops and commercializes proprietary 14-3-3eta biomarker blood tests — JOINTstat for rheumatoid arthritis and SPINEstat for axial spondyloarthritis — distributed through major clinical laboratory networks in North America and the UK.
- Ownership category
- akta.pro rank
Augurex Life Sciences industry classification
Industry- Product category
- Autoimmune Disease Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Autoimmune, Allergy & Specialized Immunology Diagnostics (HLAHAAAK)
- akta.pro secondary industries
- Autoimmune & Allergy Diagnostics (HLAAALAK), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
Keywords
Where Augurex Life Sciences is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Augurex Life Sciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations, Others
Revenue model
- Diagnostic Testing Services: Augurex's tests are offered through laboratory partners who perform the testing services. The company generates revenue through analyte-specific reagents (ASRs) sold to clinical laboratories, distribution arrangements, and licensing agreements with major lab networks (Quest, Labcorp, Sonic Healthcare, ARUP).
- Laboratory Developed Tests (LDTs): US clinical laboratories purchase Augurex's analyte-specific reagents to develop their own laboratory-developed tests, creating a recurring revenue stream from reagent sales.
Go-to-market motion1 record
Distribution channels6 records
Marketing channels4 records
Augurex Life Sciences product offering
Product offeringCore offering
Augurex develops and commercializes proprietary biomarker-based blood diagnostic tests for autoimmune conditions. The two commercial products are JOINTstat, an ELISA measuring the 14-3-3eta protein for rheumatoid arthritis diagnosis and monitoring, and SPINEstat, a first-in-class Anti-14-3-3eta Multiplex immunoassay for axial spondyloarthritis diagnosis. Augurex also sells 14-3-3eta and Anti-14-3-3eta Multiplex analyte-specific reagents (ASRs) to U.S. clinical laboratories for laboratory-developed test development, and licenses the biomarker to laboratory distribution partners including Quest Diagnostics, Labcorp, ARUP, Sonic Healthcare USA, Dynacare, and MitogenDx.
Product overview
Augurex Life Sciences is a commercial-stage diagnostics company offering a portfolio of biomarker-driven diagnostic tests for autoimmune conditions. The core products are JOINTstat® (14-3-3eta protein test) for rheumatoid arthritis diagnosis and monitoring, and SPINEstat® (Anti-14-3-3eta Multiplex) for axial spondyloarthritis diagnosis. Both tests are backed by the 14-3-3eta biomarker platform, with analyte-specific reagents (ASRs) also available for U.S. clinical laboratories to develop their own tests. The company operates as a B2B diagnostics provider, selling tests through laboratory distribution partners including Quest Diagnostics, Labcorp, ARUP Laboratories, Sonic Healthcare USA, Dynacare, and MitogenDx.
Differentiator
Problem solved
Functional benefit
Brands
- JOINTstat: 14-3-3eta protein test for diagnosing and monitoring rheumatoid arthritis. Health Canada-approved and UKCA-authorized for RA diagnosis and management.
- SPINEstat
Products and services
- JOINTstat (14-3-3eta Protein Test) ELISA-based blood diagnostic test that measures the 14-3-3eta protein for the diagnosis and monitoring of rheumatoid arthritis (RA). Health Canada-approved and UKCA-authorized for RA diagnosis and management, and supported by over 10 years of peer-reviewed clinical evidence. 93% of early RA patients are positive for 14-3-3eta, and 14-3-3eta provides 5 to 50 times greater likelihood of having RA versus healthy controls.
- SPINEstat (Anti-14-3-3eta Multiplex) First-in-class multiplex immunoassay blood test that detects autoantibodies to 14-3-3eta epitopes for the diagnosis of axial spondyloarthritis (axSpA). Differentiates axSpA from mechanical back pain with AUC 0.82, sensitivity 76.2%, and specificity 74.1%; combination of 14-3-3eta autoantibodies and CRP identifies 90% of AS patients. Health Canada-approved, UKCA-marked, and FDA Breakthrough Device Designation.
- 14-3-3eta Analyte-Specific Reagents (ASRs) Analyte-specific reagents (ASRs) for the 14-3-3eta biomarker available for purchase and use by U.S. clinical laboratories as components of diagnostic tests developed by such laboratories for detecting the 14-3-3eta protein. Distributed to clinical labs to enable laboratory-developed tests for rheumatoid arthritis.
- Anti-14-3-3eta Multiplex ASRs Analyte-specific reagents for detecting anti-14-3-3eta autoantibodies, sold to clinical laboratories for development of laboratory-developed tests to aid in the diagnosis of axial spondyloarthritis. Enables broad laboratory adoption of the SPINEstat biomarker through LDTs.
Quantifiable outcome
- 93% of early RA patients are positive for 14-3-3eta markers
- +5 more outcomes
Companies that use Augurex Life Sciences
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
Augurex Life Sciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Augurex Life Sciences partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Sonic Reference Laboratory / Sonic Healthcare USAcoreAugurex launched its 14-3-3eta test through Sonic Reference Laboratory, a division of Sonic Healthcare USA, for rheumatoid arthritis diagnosis and monitoring. The test became available December 15, 2025, expanding access across the US through Sonic's national laboratory network. Sonic Healthcare serves over 100 million patients annually across eight countries.
- MitogenDxcorePartnership with Calgary-based MitogenDx to expand access to JOINTstat testing across Canada, with particular focus on Alberta. MitogenDx, founded by Dr. Marvin Fritzler (pioneer in rheumatology diagnostics), offers the test through its laboratory network starting January 1, 2026. This partnership enhances access to advanced RA diagnostic testing and disease monitoring for clinicians and patients nationwide.
- Quest DiagnosticscoreExclusive license agreement for development of clinical laboratory-developed testing service for 14-3-3eta biomarker in the US market. Quest offers the 14-3-3eta Protein test (Test Code 91455).
- New Day DiagnosticscoreLaunch of Anti-14-3-3eta Multiplex Analyte Specific Reagents (ASRs) enabling New Day Diagnostics to develop and offer a first-in-class diagnostic test for axial spondyloarthritis. This partnership expands the availability of SPINEstat testing capabilities.
- ARUP LaboratoriescoreARUP Laboratories launched 14-3-3eta testing to enhance early diagnosis and management of rheumatoid arthritis. Offers both standalone 14-3-3eta Protein test and Early/Established RA Panel combining multiple biomarkers.
- LabcorpcoreLabcorp offers 14-3-3eta testing including standalone 14-3-3eta Protein (504550) and RheumAssure combined panel (504509) which includes RF and anti-CCP markers.
- QuidelminorDistribution arrangement for JOINTstat 14-3-3eta RUO (research use only) ELISA, enabling broader access for investigators and pharmaceutical companies to advance research on the joint damage biomarker.
- DynacarecoreDynacare launched JOINTstat testing services in Canada, making the 14-3-3eta blood test accessible to more physicians and patients across Canada. Dynacare is one of Canada's largest health solution companies.
- National Research Council of Canada (NRC)minorCollaborative agreement to develop new treatments for rheumatoid arthritis through personalized medicine by combining research and development expertise.
Scale indicators4 records
Recent moves6 records
Expansion highlights7 records
Augurex Life Sciences competitors and assessment
Company assessmentBroad incumbents
- Roche Diagnostics: Roche's cobas and Elecsys platforms include autoimmune serology assays (anti-CCP, RF, anti-dsDNA). Comparable as a broad IVD incumbent with rheumatology-adjacent test menus distributed globally.
- Thermo Fisher Scientific (Phadia): Phadia (ImmunoCAP) and the broader Specialty Diagnostics segment provide allergy and autoimmune IVD solutions at global scale. Comparable as a broad IVD incumbent with overlapping rheumatology and immunology test menus.
- Siemens Healthineers: Siemens Healthineers' Atellica and ADVIA Centaur platforms include autoimmune and inflammation assays. Comparable as a broad IVD incumbent serving rheumatology and reference lab channels.
- Bio-Rad Laboratories: Bio-Rad's Life Science and Clinical Diagnostics segments offer autoimmune and immunology assays (e.g., BioPlex 2200) widely used by rheumatology labs. Comparable as a broad IVD incumbent with overlapping autoimmune diagnostic menu.
- Abbott Diagnostics: Abbott's ARCHITECT and Alinity platforms run autoimmune and rheumatology assays in high-volume clinical labs. Comparable as a broad IVD incumbent with overlapping autoimmune test offerings.
Direct peers
- Werfen (Binding Site / Inova Diagnostics): Werfen's Inova Diagnostics and Binding Site divisions are leaders in autoimmune specialty diagnostics (ANA, anti-CCP, anti-dsDNA, ENA panels). Directly comparable as autoimmune IVD specialty providers serving rheumatology labs.
- Crescendo Bioscience (Myriad Genetics): Crescendo's Vectra DA is a multi-marker blood test for rheumatoid arthritis disease activity, sold through Myriad Genetics. Directly comparable to JOINTstat as an RA-specific biomarker test distributed via US clinical laboratories and used by rheumatologists.
- Euroimmun (Revvity / PerkinElmer): Euroimmun specializes in autoimmune and infection serology diagnostics (ANA, anti-CCP, myositis, vasculitis panels), serving rheumatology laboratories. Highly comparable as an autoimmune-focused IVD specialty company.
Regional players
- Quotient Therapeutics (molecular diagnostics adjacencies): Listed here as a placeholder: regional or specialty autoimmune diagnostic developers (e.g., Aeskulisa, Cambridge Life Sciences, AESKU.GROUP) operate in Europe with comparable autoimmune ELISA and immunoblot reagent portfolios. Comparable as autoimmune-focused specialty IVD developers serving similar lab customers.
Emerging players
- Scipher Medicine: Scipher Medicine offers PrismRA, a blood-based molecular signature test for rheumatoid arthritis treatment selection. Comparable as an emerging molecular/blood diagnostics company targeting RA rheumatology prescribing decisions.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Augurex Life Sciences social profiles
Digital presenceAugurex Life Sciences compliance and trust
Trust signalCompliance2 records
Augurex Life Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Augurex Life Sciences leadership team
Management profileNumber of profiles
Profiles8 records
Augurex Life Sciences funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Augurex Life Sciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Augurex Life Sciences
What does Augurex Life Sciences do?
Augurex develops and commercializes proprietary biomarker-based blood diagnostic tests for autoimmune conditions. The two commercial products are JOINTstat, an ELISA measuring the 14-3-3eta protein for rheumatoid arthritis diagnosis and monitoring, and SPINEstat, a first-in-class Anti-14-3-3eta Multiplex immunoassay for axial spondyloarthritis diagnosis. Augurex also sells 14-3-3eta and Anti-14-3-3eta Multiplex analyte-specific reagents (ASRs) to U.S. clinical laboratories for laboratory-developed test development, and licenses the biomarker to laboratory distribution partners including Quest Diagnostics, Labcorp, ARUP, Sonic Healthcare USA, Dynacare, and MitogenDx.
Is Augurex Life Sciences a public or private company?
Augurex Life Sciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Augurex Life Sciences founded?
Augurex Life Sciences was founded in 2011. It employs 1 to 10 people.
Where is Augurex Life Sciences based?
Augurex Life Sciences is headquartered in Vancouver, Canada, in the North America region.
How does Augurex Life Sciences make money?
Two revenue lines are on record. Diagnostic Testing Services are the primary driver. The others are laboratory Developed Tests (LDTs).
Who are Augurex Life Sciences's main competitors?
Broad incumbents on record are Roche Diagnostics, Thermo Fisher Scientific (Phadia), Siemens Healthineers, Bio-Rad Laboratories and Abbott Diagnostics. Direct peers are Werfen (Binding Site / Inova Diagnostics), Crescendo Bioscience (Myriad Genetics) and Euroimmun (Revvity / PerkinElmer). Quotient Therapeutics (molecular diagnostics adjacencies) is listed as a regional player. Scipher Medicine is listed as an emerging player.
Does Augurex Life Sciences have an API?
No public API is recorded for Augurex Life Sciences.
What industry is Augurex Life Sciences in?
Augurex Life Sciences's product category is Autoimmune Disease Diagnostics. Its primary akta.pro industry code is HLAHAAAK, Autoimmune, Allergy & Specialized Immunology Diagnostics, with a secondary code of HLAAALAK, Autoimmune & Allergy Diagnostics. Its NAICS code is 325413 and its SIC code is 2835.